Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
AKRO holding history
Akero Therapeutics, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AKRO overviewAll 13F holders of AKROFull Q2 2026 holdings
- Shares (Q4 2025)
- 0
- Sold out in Q4 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 12
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | $0 | 0.0% | −1,217,044−100.0% | Sold out | Holders |
| Q3 2025 | 1,217,044 | $57.8M | 0.1% | −201,171−14.2% | Reduced | Holders |
| Q2 2025 | 1,418,215 | $75.7M | 0.1% | −189,627−11.8% | Reduced | Holders |
| Q1 2025 | 1,607,842 | $65.1M | 0.1% | +1,332,768+484.5% | Added | Holders |
| Q4 2024 | 275,074 | $7.65M | <0.1% | +275,074 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −120,674−100.0% | Sold out | Holders |
| Q1 2024 | 120,674 | $3.05M | <0.1% | +120,674 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −260,535−100.0% | Sold out | Holders |
| Q3 2023 | 260,535 | $13.2M | <0.1% | −662,523−71.8% | Reduced | Holders |
| Q2 2023 | 923,058 | $43.1M | 0.1% | −158,667−14.7% | Reduced | Holders |
| Q1 2023 | 1,081,725 | $41.4M | 0.1% | −421,639−28.0% | Reduced | Holders |
| Q4 2022 | 1,503,364 | $82.4M | 0.2% | +752,524+100.2% | Added | Holders |
| Q3 2022 | 750,840 | $25.6M | 0.1% | −254,842−25.3% | Reduced | Holders |
| Q2 2022 | 1,005,682 | $9.50M | <0.1% | +1,005,682 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −4,082−100.0% | Sold out | Holders |
| Q4 2021 | 4,082 | $86.0K | <0.1% | +4,082 | New | Holders |